Alx Oncology Holdings (ALXO) EBT (2019 - 2026)

Alx Oncology Holdings has disclosed EBT across 8 years of filings, most recently posting -$18.1 million for Q1 2026.

• EBT for Q1 2026 came in at -$18.1 million, up 41.08% year-over-year; the trailing twelve-month figure through Mar 2026 was -$89.0 million (up 31.52% YoY), and the FY2025 annual result was -$101.7 million, up 24.18% from the prior year.
• EBT came in at -$18.1 million for Q1 2026 at Alx Oncology Holdings, up from -$22.8 million in the prior quarter.
• In the past five years, EBT ranged from a high of $91.1 million in Q4 2023 to a low of -$51.0 million in Q3 2023.
• The 5-year median for EBT is -$30.6 million (2022), against an average of -$23.7 million.
• Across the five-year window, EBT plunged 1555.03% in 2022 and jumped 397.18% in 2023, its largest moves.
• Alx Oncology Holdings' EBT stood at -$30.6 million in 2022, then surged by 397.18% to $91.1 million in 2023, then slumped by 132.02% to -$29.2 million in 2024, then gained by 21.71% to -$22.8 million in 2025, then grew by 20.66% to -$18.1 million in 2026.
• The last three EBT figures came in at -$18.1 million (Q1 2026), -$22.8 million (Q4 2025), and -$22.1 million (Q3 2025), per Business Quant data.